b
r
c
great
interest
involv
biosynthesi
andor
catabol
degrad
sever
nucleosid
analogu
biolog
therapeut
relev
howev
due
lack
stabilis
group
difficult
synthes
stabl
prodrug
compound
order
overcom
lack
stabil
synthesi
carbasugar
analogu
envis
herein
prepar
seri
prodrug
two
carbocycl
analogu
use
phosphoramid
protid
technolog
along
biolog
evalu
hiv
cancer
cell
prolifer
report
essenti
constitu
larger
biomolecul
play
divers
import
role
mani
physiolog
process
particular
key
intermedi
metabol
carbohydr
critic
transform
nucleosid
among
fig
catabol
product
thymidin
phosphorylas
tp
ec
nucleosid
phosphorylas
np
enzym
involv
pyrimidin
nucleosid
salvag
pathway
howev
tp
also
shown
respons
promot
angiogenesi
increas
tp
express
level
found
mani
solid
tumour
often
correl
neovascularis
onset
metastasi
poor
prognosi
previou
studi
aim
prepar
novel
inhibitor
np
anticanc
agent
identifi
fig
found
inhibit
varieti
pyrimidin
purin
np
prefer
uridineand
inosinehydrolyz
enzym
compound
effici
prevent
enzymat
breakdown
therapeut
analogu
deoxyuridin
fdurd
studi
also
demonstr
difficulti
synthes
phosphoramid
prodrug
anomer
posit
found
unstabl
overcom
instabl
shown
introduct
fluorin
atom
enabl
synthesi
phosphoramid
prodrug
compound
respect
fig
within
context
recent
report
synthesi
seri
phosphonamid
prodrug
anoth
stabl
analogu
anomer
oxygen
replac
methylen
group
continu
interest
prepar
prodrug
stabl
analogu
report
applic
protid
approach
two
carbasugar
analogu
term
carbasugar
refer
famili
compound
oxygen
atom
furanos
sugar
ring
replac
methylen
group
carbasugar
chemic
stabl
toward
degrad
sugar
analogu
time
due
resembl
natur
sugar
may
still
recogn
enzym
well
known
therapeut
potenti
drug
bear
phosphat
moieti
decreas
neg
charg
phosphat
group
physiolog
ph
overcom
problem
protid
technolog
success
appli
past
variou
nucleosid
sugar
analogu
mind
herein
report
synthesi
seri
prodrug
http
elsevi
ltd
right
reserv
report
recent
paper
schinazi
et
al
remov
neutral
condit
perhap
without
affect
phosphoramid
moieti
hydroborationoxid
reaction
investig
use
differ
boran
reagent
dicyclohexylboran
bh
best
yield
obtain
bh
expect
addit
carbocycl
format
regioisom
also
observ
aepim
compound
isol
wherea
alpha
beta
epim
compound
observ
ratio
nmr
spectra
compound
agreement
literatur
adapt
optim
hydrobor
condit
compound
obtain
carbocycl
aepim
regioisom
mixtur
epim
ratio
yield
respect
order
biolog
evalu
parent
carbasugar
eventu
compar
activ
correspond
phosphoramid
prodrug
also
prepar
triol
regioisom
hydrogen
reaction
compound
nmr
data
compound
show
symmetr
meso
system
confirm
prepar
aepim
carbocycl
intermedi
hand
studi
reaction
appropri
phosphorochlorid
compound
scheme
tabl
presenc
differ
base
tbumgcl
nmi
pk
et
n
pk
nbuli
pk
ca
differ
solvent
thf
toluen
shown
tabl
best
result
obtain
et
n
nmi
use
entri
particular
nmi
mol
first
ad
solut
carbocycl
toluen
reaction
mixtur
cool
follow
addit
et
n
equiv
desir
phosphorochlorid
equiv
reaction
monitor
p
nmr
analysi
format
desir
phosphoryl
compound
complet
signal
ppm
p
nmr
crude
purifi
column
chromatographi
yield
cbzprotect
prodrug
submit
hydrogen
reaction
afford
final
phosphoramid
prodrug
follow
methodolog
six
prodrug
carbasugar
synthes
yield
rang
two
step
scheme
strategi
appli
regioisom
afford
two
prodrug
yield
yield
prodrug
subject
biolog
evalu
antivir
antiprolif
agent
none
prodrug
show
activ
cytostat
effect
cem
cell
tabl
parent
carbocycl
analogu
cbzprotect
deriv
activ
either
howev
regioisom
cbzprotect
deriv
show
pronounc
antihiv
activ
cem
cell
cultur
lm
rang
compar
correspond
cem
cell
tabl
evalu
hiv
cell
cultur
antivir
activ
confirm
low
micromolar
concentr
without
mark
cytotox
cc
lm
unfortun
correspond
prodrug
devoid
signific
antivir
activ
tabl
assess
antiprolif
activ
show
pronounc
inhibit
prolifer
murin
leukemia
cell
human
tlymphocyt
cell
cem
cervix
carcinoma
hela
cell
tabl
probe
result
incub
compound
carboxypeptidas
aceton
trizma
buffer
perform
assay
follow
p
nmr
fig
compound
slowli
metabol
h
start
materi
still
present
slow
process
may
explain
lack
activ
kind
prodrug
antihiv
activ
low
micromolar
concentr
surpris
worth
explor
respect
molecular
mechan
antivir
action
inde
notic
compound
show
measur
activ
lm
wide
varieti
virus
includ
herp
simplex
viru
type
vaccinia
viru
hel
cell
cultur
vesicular
stomat
viru
vsv
coxsacki
viru
respiratori
syncyti
viru
rsv
hela
cell
cultur
parainfluenza
sindbi
viru
punta
toro
viru
vero
cell
cultur
influenza
viru
influenza
viru
b
mdck
cell
cultur
felin
corona
viru
felin
herpesviru
crfk
cell
cultur
find
make
compound
highli
select
hiv
revers
transcriptas
exclud
direct
target
sinc
compound
found
inact
enzym
data
shown
summari
prepar
sever
prodrug
two
carbasugar
analogu
biolog
evalu
prodrug
show
inhibitori
activ
hiv
cancer
cell
prolifer
howev
note
parent
carbocycl
synthet
intermedi
show
micromolar
activ
hiv
investig
elucid
underli
mechan
exert
antivir
activ
hiv
perform
particular
synthet
rout
hydroxymethyl
investig
order
confirm
whether
compound
inde
act
inhibitor
np
applic
prodrug
approach
also
consider
suspens
isopropoxydimethylsilyl
methyl
g
mmol
potassium
fluorid
g
mmol
equiv
khco
g
mmol
equiv
hydrogen
peroxid
ml
methanolthf
ml
heat
reflux
h
reaction
mixtur
dilut
acoet
ml
sodium
thiosulf
g
magnesium
sulfat
g
ad
reaction
mixtur
stir
room
temperatur
min
filtrat
though
pad
celit
filtrat
evapor
dryness
crude
purifi
column
chromatographi
eluent
hexaneacoet
order
give
compound
g
mmol
colorless
oil
solut
compound
mg
mmol
thf
ml
ad
nah
slurri
mg
mmol
equiv
reaction
mixtur
stir
room
temperatur
h
addit
bnbr
mmol
equiv
reaction
mixtur
heat
reflux
h
addit
crush
ice
reaction
mixtur
stir
min
dilut
acoet
ml
organ
phase
wash
h
ml
brine
ml
dri
solut
compound
g
mmol
dmap
g
mmol
equiv
ch
cl
ml
ad
dropwis
cbzcl
ml
mmol
equiv
reaction
mixtur
stir
room
temperatur
h
dilut
ch
cl
ml
wash
hcl
n
ml
h
ml
organ
phase
dri
mgso
solvent
evapor
dryness
purif
crude
column
chromatographi
eluent
peacoet
gave
compound
g
mmol
colorless
oil
solut
compound
mg
mmol
thf
ml
ad
dropwis
solut
bh
mmol
equiv
reaction
mixtur
stir
h
room
temperatur
h
addit
naoh
n
h
reaction
mixtur
stir
room
temperatur
h
reaction
mixtur
dilut
h
ml
acoet
ml
aqueou
phase
extract
acoet
ml
combin
organ
phase
dri
mgso
solvent
evapor
dryness
purif
crude
column
chromatographi
eluent
peacoet
gave
compound
mg
mmol
compound
mg
mmol
colorless
oil
mmol
equiv
reaction
mixtur
stir
h
addit
ml
naoh
n
ml
h
reaction
mixtur
stir
room
temperatur
h
reaction
mixtur
dilut
h
ml
acoet
ml
aqueou
phase
extract
acoet
ml
combin
organ
phase
dri
mgso
solvent
evapor
dryness
purif
crude
column
chromatographi
eluent
peacoet
gave
compound
mg
mmol
compound
mg
mmol
colorless
oil
solut
etoh
c
sm
ad
pdc
mgmmol
reaction
mixtur
stir
room
temperatur
h
atmospher
consum
h
pd
filtrat
pad
celit
solvent
evapor
dryness
afford
desir
final
compound
quantit
yield
solut
etoh
c
sm
ad
pdc
mgmmol
reaction
mixtur
stir
room
temperatur
h
atmospher
consum
h
pd
filtrat
pad
celit
solvent
evapor
dryness
afford
desir
final
compound
quantit
yield
compound
synthes
accord
method
describ
obtain
yield
abp
p
r
mixtur
diastereoisom
compound
synthes
accord
method
describ
obtain
yield
aepim
mixtur
accord
noesi
experi
signal
noesi
experi
ratio
p
p
r
know
one
p
one
p
r
compound
synthes
accord
method
describ
obtain
yield
mixtur
two
diastereoisom
